The new company, to be called Jacobs Douwe Egberts (JDE), is expected to hold market positions in more than two dozen countries with a strong emerging market presence.
Under the terms of the agreement, Bayer AG will acquire Mercks existing OTC business, including the global trademark and prescription rights for Claritin and Afrin.